TuHURA Biosciences (HURA) Retained Earnings (2011 - 2026)
TuHURA Biosciences (HURA) posted quarterly Retained Earnings of -$148.7 million for Q1 2026, down 26.26% year-over-year from -$201.7 million in Q1 2025, and down 5.34% quarter-over-quarter from -$141.2 million in Q4 2025.
TuHURA Biosciences (HURA) Retained Earnings (2011 - 2026) Analysis & Trends
TuHURA Biosciences' Retained Earnings history runs 16 years deep, the most recent figure standing at -$148.7 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 26.26% year-over-year to -$148.7 million; the TTM figure through Mar 2026 stood at -$148.7 million (down 26.26% YoY), while the FY2025 annual figure was -$141.2 million, down 27.05% from the prior year.
- Retained Earnings for Q1 2026 stood at -$148.7 million, down from -$141.2 million in the prior quarter.
- The five-year high for Retained Earnings was $21000.0 in Q3 2022, with the low at -$162.1 million in Q3 2024.
- The 5-year median for Retained Earnings is -$127.3 million (2025), against an average of -$94.7 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings surged 100.02% in 2023, then tumbled 750338.1% in 2024.
- TuHURA Biosciences' Retained Earnings stood at $21000.0 in 2022, then slumped by 421409.51% to -$88.5 million in 2023, then slipped by 25.6% to -$111.1 million in 2024, then retreated by 27.05% to -$141.2 million in 2025, then retreated by 5.34% to -$148.7 million in 2026.
- Business Quant data shows HURA's Retained Earnings at -$148.7 million in Q1 2026, -$141.2 million in Q4 2025, and -$134.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | -157.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -148.72 Mn |
| Dec 31, 2025 | -141.18 Mn |
| Sep 30, 2025 | -134.42 Mn |
| Jun 30, 2025 | -127.32 Mn |
| Mar 31, 2025 | -117.79 Mn |
| Dec 31, 2024 | -111.12 Mn |
| Sep 30, 2024 | -162.05 Mn |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | -157.55 Mn |
| Dec 31, 2023 | -88.47 Mn |
| Sep 30, 2023 | -154.51 Mn |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 21,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 21,000.00 |
| Jun 30, 2022 | -136.36 Mn |
| Mar 31, 2022 | -130.91 Mn |
| Dec 31, 2021 | 21,000.00 |
| Sep 30, 2021 | 21,000.00 |
| Jun 30, 2021 | -111.23 Mn |